China begins new knee OA cell study to evaluate a human adipose-derived mesenchymal precursor cell therapy

KNEE OA CELL THERAPY TRIALS IN CHINA (Orthopedics This Week)
Renji Hospital in Shanghai, a tertiary hospital affiliated with Shanghai Jiao Tong University School of Medicine, has given approval for a Phase IIb clinical trial for ReJoin. ReJoin is a human adipose-derived mesenchymal precursor cell therapy bio-engineered for knee osteoarthritis (KOA) by Cellular Biomedicine Group, Inc.
The trial will test the safety and efficacy of intra-articular injections of autologous (patient’s own) ReJoin formula in order to reduce inflammation and repair damaged joint cartilage.
“The approval of our Phase...